Research

Hormonal

Rimonabant, a CB1 receptor antagonist, was withdrawn due to an increased risk of serious psychiatric adverse events, including depression and suicidal ideation.

Rimonabant was withdrawn from the market because it significantly increased the risk of depression and suicidal thoughts compared to placebo.

GoodRefutesHIGH confidence
The adverse psychiatric events were observed in 26% of the participants in the rimonabant group compared with 14% in the placebo group in the same 4 studies
Jun Goo Kang et al. · Diabetes & Metabolism Journal · 2012

Why this rating

Based on the RIO program (4 phase 3 trials, >6,000 patients).

Source

Anti-Obesity Drugs: A Review about Their Effects and Safety

Jun Goo Kang et al. · Diabetes & Metabolism Journal · 2012

DOI 10.4093/dmj.2012.36.1.13

narrative_reviewCited 587×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →